Modifying disease therapy in multiple sclerosis and breast cancer: case report

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Modifying disease therapy in multiple sclerosis and breast cancer: case report ; volume:82 ; number:S 01 ; year:2024 ; 01
Konferenz: 25th BCTRIMS Annual Meeting; 2024-06-05; Tivoli Mofarrej São Paulo - SP
Arquivos de neuro-psiquiatria ; 82, Heft S 01 (2024), 01

Contributor: Nascimento, Felipe
Pereira, Rodrigo
Rios, Marianela
Almeida, Danilo
Araújo, Thiago
Chamma, Pedro
Mansur, Leticia
Pimentel, Maria Lucia Vellutini

DOI: 10.1055/s-0044-1789386

URN: urn:nbn:de:101:1-2412121020511.979152415940

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nascimento, Felipe
Pereira, Rodrigo
Rios, Marianela
Almeida, Danilo
Araújo, Thiago
Chamma, Pedro
Mansur, Leticia
Pimentel, Maria Lucia Vellutini

Other Objects (12)

Multiple sclerosis: disease modifying therapy and the human leukocyte antigen

Current Disease-Modifying Therapies in Multiple Sclerosis

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

Fingolimod Therapy for Multiple Sclerosis

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Multiple sclerosis: disease modifying therapy and the human leukocyte antigen

Current Disease-Modifying Therapies in Multiple Sclerosis

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

Fingolimod Therapy for Multiple Sclerosis

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Multiple sclerosis: disease modifying therapy and the human leukocyte antigen

Current Disease-Modifying Therapies in Multiple Sclerosis

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

Fingolimod Therapy for Multiple Sclerosis

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Modifying disease therapy in multiple sclerosis and breast cancer: case report

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Multiple sclerosis: disease modifying therapy and the human leukocyte antigen

Current Disease-Modifying Therapies in Multiple Sclerosis

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

Fingolimod Therapy for Multiple Sclerosis

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Multiple sclerosis: disease modifying therapy and the human leukocyte antigen

Current Disease-Modifying Therapies in Multiple Sclerosis

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

Fingolimod Therapy for Multiple Sclerosis

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Multiple sclerosis: disease modifying therapy and the human leukocyte antigen

Current Disease-Modifying Therapies in Multiple Sclerosis

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis

Fingolimod Therapy for Multiple Sclerosis

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Related objects

Reset password